LEGN
From science project to cash machine?
Legend Biotech is starting to look less like a biotech science fair and more like an actual business. In Q2, revenue climbed 52% year over year, and the company posted $57.7 million in operating income — a pretty loud way of saying the old “capital-intensive biotech” label may be losing its grip.
CARVYKTI is doing the heavy lifting
The real star here is CARVYKTI, which delivered 50% sales growth as the therapy keeps moving earlier in the treatment cycle and expanding globally. More than 70% of use is now in 2L–4L settings, which is the kind of adoption mix investors like because it suggests the product is becoming part of standard care, not just a last-resort option.
Why investors should care
This is the part where the story gets interesting: profitable cell therapy companies are a lot rarer than promising ones. If Legend can keep converting CARVYKTI momentum into steady earnings, the market may start treating the company more like a durable commercial platform and less like a biotech roulette wheel.
Big picture: the pipeline may not be the headline anymore — the P&L is.